This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Schott Pharma cartriQ® ready-to-use (RTU), small-volume sterile cartridges are suitable for administering insulin and the GLP-1 drugs used to treat diabetes and obesity, while the large-volume cartridges are suitable for storing high-value biologics to treat cancer or Parkinson's disease, for example. The containers are washed, depyrogenated, siliconized, and steam sterilized, allowing CDMOs and pharma companies to immediately start the filling process without having to handle the preparatory steps themselves.
Made of high-quality borosilicate glass, the RTU cartridges provide improved drug stability due to an optimized leachable behavior of the glass and prequalified components, such as combi-seals and plungers. The small-volume cartridges are compatible with hand-held injection devices, such as pens and auto-injectors, while the large-volume products are suited for wearable large-volume injectors (LVIs).
As part of the Schott iQ® platform, which also includes RTU syringes and vials, the RTU cartridges are delivered in an industry-standard nest and tub and remain nested throughout the filling process, eliminating glass-to-glass contact and allowing pharma companies full flexibility when filling different medications in different containers on one filling line.
“With our RTU cartridges, we’re able to help pharma companies, CDMOs, and startups alike to maintain a short time to market, while increasing processing and output efficiency,” explains Elisa Wiesner, global product manager for bulk and sterile cartridges at Schott Pharma. “Subsequently, the drugs can reach the patients in a timely and safe manner.”
